Metformin and Abdominal Aortic Aneurysm

Research output: Contribution to journalEditorial (Academic Journal)peer-review

16 Citations (Scopus)
337 Downloads (Pure)


Recently published data from a number of sources appear to suggest that the oral hypoglycaemic agent metformin may prevent abdominal aortic aneurysm (AAA) development, attenuate growth, and perhaps even prevent rupture. Previous studies have hinted that hypoglycaemic agents might reduce AAA expansion.1 The latest data, specific to metformin are compelling. Metformin is a biologically plausible drug since it has a wide range of effects on inflammation and metabolism. Potentially exciting observations remain preliminary and should be interpreted with caution.
Original languageEnglish
Pages (from-to)679-680
Number of pages2
JournalEuropean Journal of Vascular and Endovascular Surgery
Issue number6
Early online date5 Oct 2017
Publication statusPublished - Dec 2017

Structured keywords

  • Centre for Surgical Research


Dive into the research topics of 'Metformin and Abdominal Aortic Aneurysm'. Together they form a unique fingerprint.

Cite this